Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsArizona Medicaid Qulipta Prior Auth | OpenPayer
    Ask Trek AI about this page
    CurrentArizona Complete HealthPolicy AZ.CP.PHAR.566

    Clinical Policy: Atogepant (Qulipta)

    Customize your policy alerts

    Sign up for Arizona Complete Health Policy AZ.CP.PHAR.566 alerts

    Get alerted when Policy AZ.CP.PHAR.566 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Prior authorization and medical-necessity coverage criteria for Qulipta (atogepant) for prevention of episodic migraine in adults enrolled in Arizona Medicaid.

    Policy Summary
    PayerArizona Complete Health
    PolicyClinical Policy: Atogepant (Qulipta)
    Policy CodePolicy AZ.CP.PHAR.566
    Change TypeNo material change
    Effective DateFeb 1, 2022
    Last ReviewFeb 1, 2022
    Next Review DateNot specified
    Key ActionSubmit prior authorization documentation showing that all applicable approval criteria are met.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    Adults with episodic migraineCovered population
    ≥4 days/monthMigraine threshold
    2 oral + 2 CGRPRequired prior failures
    60 mg/dayMaximum dose
    3 / 6 monthsApproval duration

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Coverage Criteria

    Initial therapy — migraine prophylaxis

    Covered when all of the following initial approval criteria are met:

    Initial migraine prophylaxis criteria

    • The member has a diagnosis of episodic migraine and experiences at least 4 migraine days per month for at least 3 months.≥4 migraine days/month for ≥3 months
    • The member does not have chronic migraine, defined as at least 15 headache days per month with at least 8 migraine days per month for at least 3 months.<15 headache days/month or <8 migraine days/month, or duration <3 months
    • Qulipta is prescribed by or in consultation with a neurologist, headache specialist, or pain specialist.
    • The member is at least 18 years old.≥18 years
    • Oral preventive therapy requirement

      • The member has failed at least two oral migraine preventive therapies from different therapeutic classes—antiepileptic drugs, beta-blockers, or antidepressants—each used for 8 weeks.At least 2 therapies; 8 weeks per therapy
      • Clinically significant adverse effects were experienced with the required oral preventive therapies.
      • All applicable oral preventive therapy options are contraindicated.
    • CGRP inhibitor requirement

      • The member has failed 3-month trials of two CGRP inhibitors used for migraine prophylaxis.2 CGRP inhibitors; 3 months per therapy

        Prior authorization may be required for the alternative CGRP inhibitors.

      • Clinically significant adverse effects were experienced with the required CGRP inhibitor trials.
      • All applicable CGRP inhibitor options are contraindicated.
    • Qulipta is not prescribed concurrently with Botox or another CGRP inhibitor, including Aimovig, Ajovy, Emgality, Nurtec ODT, Ubrelvy, or Vyepti.
    • The requested dose does not exceed 60 mg per day.≤60 mg/day

    Continuation therapy — migraine prophylaxis

    Covered when all of the following continued-therapy criteria are met:

    Continued migraine prophylaxis criteria

    • Current therapy or prior approval

      • The member is currently receiving Qulipta through the Centene benefit.
      • The member previously met the initial approval criteria.
    • The member has experienced and maintained a positive response to therapy, evidenced by a reduction in migraine days per month from baseline.
    • Qulipta is not prescribed concurrently with Botox or another CGRP inhibitor, including Aimovig, Ajovy, Emgality, Nurtec ODT, Ubrelvy, or Vyepti.
    • Dose requirement

    Other diagnoses/indications

    Other diagnoses or indications are handled under the applicable off-label use policy:

    Other diagnoses or indications

    • For continued therapy, the member is currently receiving the medication through the Centene benefit and documentation supports a positive response to therapy.

      Approval duration is the duration of the request or 12 months, whichever is less.

    • Refer to the off-label use policy for the relevant line of business when the diagnosis is not specifically listed under the policy's diagnoses or indications for which coverage is not authorized.

      For Arizona Medicaid, refer to AZ.CP.PMN.53. Initial requests for other diagnoses are referred under this pathway; continued-therapy requests may also use this pathway when applicable.

    Non-FDA-approved indications that are not addressed in this policy are not authorized unless sufficient documentation of efficacy and safety is provided according to the applicable off-label use policy, AZ.CP.PMN.53, for Arizona Medicaid.

    Concurrent use is not covered under the approval criteria: Qulipta must not be prescribed with Botox or another CGRP inhibitor, including Aimovig, Ajovy, Emgality, Nurtec ODT, Ubrelvy, or Vyepti.

    Coverage Parameters

    Migraine frequency
    DiagnosisEpisodic migraine
    FrequencyAt least 4 migraine days per month
    DurationFor at least 3 months
    Chronic migraine exclusion threshold
    Headache daysAt least 15 headache days per month
    Migraine daysAt least 8 migraine days per month
    DurationFor at least 3 months

    Provider Requirements and Denial Risks

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required for Qulipta requests. Submit documentation demonstrating that the member meets all applicable approval criteria, including any required approval documentation for prerequisite therapies.

    • Submit the clinical documentation supporting the request with the prior authorization submission.
    Step Therapy

    Oral Step-Therapy Requirement

    Document failure of at least two oral migraine preventive therapies, with each trial lasting 8 weeks and involving different therapeutic classes. The requirement may be waived when clinically significant adverse effects are experienced or all listed options are contraindicated.

    • Antiepileptic drugs, such as divalproex sodium, sodium valproate, or topiramate.
    • Beta-blockers, such as metoprolol, propranolol, or timolol.
    • Antidepressants, such as amitriptyline or venlafaxine.

    Medication and Indication Background

    Atogepant (Qulipta) is an oral calcitonin gene-related peptide receptor antagonist. The FDA-approved indication addressed by this policy is the preventive treatment of episodic migraine in adults. The policy distinguishes episodic migraine from chronic migraine when evaluating coverage.

    Definitions

    Chronic migraine
    Headache daysAt least 15 headache days per month
    Migraine daysAt least 8 migraine days per month
    DurationFor at least 3 months
    CGRP
    AbbreviationCGRP
    Full termCalcitonin gene-related peptide
    Policy referenceCGRP inhibitors are used for migraine prophylaxis

    Initial Migraine Prophylaxis

    Initial migraine prophylaxis

    Initial migraine prophylaxis approval requires all of the following:

    Initial migraine prophylaxis criteria

    • Diagnosis is episodic migraine, with at least 4 migraine days per month for at least 3 months.≥4 migraine days/month for ≥3 months
    • The member does not have chronic migraine, defined as at least 15 headache days per month with at least 8 migraine days per month for at least 3 months.
    • Qulipta is prescribed by or in consultation with a neurologist, headache specialist, or pain specialist.
    • The member is at least 18 years old.≥18 years

    Continued Migraine Prophylaxis

    Continued migraine prophylaxis

    Continued therapy for migraine prophylaxis must meet all of the following:

    Continuation criteria

    • Current therapy or prior approval

      • The member is currently receiving Qulipta through the Centene benefit.
      • The member previously met the initial approval criteria.
    • The member has experienced and maintained a positive response to therapy, shown by reduced migraine days per month from baseline.
    • Qulipta is not prescribed concurrently with Botox or another CGRP inhibitor.

    Required Prior Therapy Trials

    RequirementTherapeutic classes and examplesDuration and failure standard
    Trial and failure of at least two oral migraine preventive therapies from different therapeutic classesAntiepileptic drugs (e.g., divalproex sodium, sodium valproate, topiramate); beta-blockers (e.g., metoprolol, propranolol, timolol); antidepressants (e.g., amitriptyline, venlafaxine)Each therapy must be used for 8 weeks. Clinically significant adverse effects or contraindication of all options may satisfy the requirement.
    RequirementExamplesDuration and failure standard
    Trial and failure of two CGRP inhibitors used for migraine prophylaxisAimovig®, Ajovy®, or Emgality®Each trial must last 3 months. Clinically significant adverse effects or contraindication of all options may satisfy the requirement; prior authorization may be required.

    Qulipta Quantity Limit

    Quantity limits
    DrugQulipta (atogepant)
    Maximum covered dose60 mg per day
    Dosing frequencyOnce daily
    Policy Summary
    PayerArizona Complete Health
    PolicyClinical Policy: Atogepant (Qulipta)
    Policy CodePolicy AZ.CP.PHAR.566
    Change TypeNo material change
    Effective DateFeb 1, 2022
    Last ReviewFeb 1, 2022
    Next Review DateNot specified
    Key ActionSubmit prior authorization documentation showing that all applicable approval criteria are met.
    SourceLink
    On This Page
    Coverage CriteriaCoverage ParametersProvider Requirements and Denial RisksMedication and Indication BackgroundDefinitionsInitial Migraine ProphylaxisContinued Migraine ProphylaxisRequired Prior Therapy TrialsQulipta Quantity Limit
  1. No dose increase is requested.
  2. If a dose increase is requested, the new dose does not exceed 60 mg per day.≤60 mg/day
  3. Oral preventive therapy trial
    Therapy typeOral migraine preventive therapy
    Required trial8 weeks per therapy
    SelectionTherapies must be from different therapeutic classes
    CGRP inhibitor trial
    Therapy typeCGRP inhibitor used for migraine prophylaxis
    Required trial3 months per therapy
    Number of therapiesTwo CGRP inhibitors
    Maximum Qulipta dose
    Maximum dose60 mg per day
    Available strengths10 mg, 30 mg, or 60 mg
    AdministrationOrally once daily
    Step Therapy

    CGRP Inhibitor Trials

    Document failure of two CGRP inhibitors used for migraine prophylaxis, with a 3-month trial of each. The trial requirement may be waived when clinically significant adverse effects are experienced or all applicable options are contraindicated.

    • Examples include Aimovig, Ajovy, and Emgality.
    • Prior authorization may be required for the CGRP inhibitor trials.
    Documentation Required

    Clinical-Supporting Documentation

    Submit clinical-supporting documentation demonstrating that the member meets all approval criteria. Acceptable support may include office chart notes, laboratory results, or other relevant clinical information.

    • Ensure submitted records support the diagnosis, treatment history, clinical status, and requested therapy.
    Documentation Required

    Initial Request Documentation

    For an initial request, document episodic migraine with at least 4 migraine days per month for at least 3 months, age 18 years or older, and prescribing by or consultation with a neurologist, headache specialist, or pain specialist.

    • Include the member's migraine diagnosis and frequency.
    • Document the required oral preventive therapy failures and CGRP inhibitor trials, including durations, therapeutic classes, adverse-effect exceptions, or contraindications.
    • Confirm that the member does not have chronic migraine, that Qulipta is not being prescribed with Botox or another CGRP inhibitor, and that the prescribed dose is no more than 60 mg per day.
    Documentation Required

    Continuation Documentation

    For continuation requests, document that the member is currently receiving Qulipta through the Centene benefit or previously met the initial approval criteria, and that therapy continues to provide a positive response.

    • Document a reduction in migraine days per month from baseline that has been maintained.
    • Confirm no concurrent Botox or other CGRP inhibitor therapy.
    • For a dose increase, document that the new dose does not exceed 60 mg per day.
    • Standard approval duration is 6 months.
    Denial Risk

    Chronic Migraine Denial Risk

    Coverage may be denied when the member has chronic migraine. Chronic migraine is defined as at least 15 headache days per month, including at least 8 migraine days per month, for at least 3 months.

    • Document migraine and headache-day frequency over the required 3-month period.
    Denial Risk

    Concurrent Migraine Therapies

    Coverage may be denied when Qulipta is prescribed concurrently with Botox or another CGRP inhibitor.

    • Other CGRP inhibitors include Aimovig, Ajovy, Emgality, Nurtec ODT, Ubrelvy, and Vyepti.
    • Confirm that concurrent migraine preventive therapy is not being used.
    Denial Risk

    Non-FDA-Approved Indication

    Coverage is not authorized for non-FDA-approved indications that are not addressed by this policy. An exception may apply when sufficient documentation of efficacy and safety supports the indication under the applicable off-label use policy.

    • For Arizona Medicaid, refer to off-label use policy AZ.CP.PMN.53 when applicable.
    Denial Risk

    Dose Exceeds Maximum

    A request may be denied when the prescribed Qulipta dose exceeds the policy maximum.

    • Maximum dose: 60 mg per day.
    • For continuation dose increases, document that the new dose remains at or below 60 mg per day.
    MHD
    AbbreviationMHD
    Full termMonthly Headache Day
    Measurement periodMonthly
    MMD
    AbbreviationMMD
    Full termMonthly Migraine Days
    Measurement periodMonthly
  4. Oral preventive therapy requirement

    • Failure of at least two oral migraine preventive therapies from different therapeutic classes—antiepileptic drugs, beta-blockers, or antidepressants—each used for 8 weeks.At least 2 therapies; 8 weeks per therapy
    • Clinically significant adverse effects occurred with the required oral preventive therapies.
    • All applicable oral preventive therapies are contraindicated.
  5. CGRP inhibitor requirement

    • Failure of 3-month trials of two CGRP inhibitors used for migraine prophylaxis.2 CGRP inhibitors; 3 months per therapy
    • Clinically significant adverse effects occurred with the required CGRP inhibitor trials.
    • All applicable CGRP inhibitors are contraindicated.
  6. Qulipta is not prescribed concurrently with Botox or another CGRP inhibitor.
  7. The dose does not exceed 60 mg per day.≤60 mg/day
  8. Dose increase

    • No dose increase is requested.
    • If a dose increase is requested, the new dose does not exceed 60 mg per day.≤60 mg/day